- Home
- ACHR vs MDGL Comparison
ACHR vs MDGL Comparison
Compare ACHR & MDGL Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- ACHR
- MDGL
- Stock Information
- Founded
- ACHR 2018
- MDGL 2011
- Country
- ACHR United States
- MDGL United States
- Employees
- ACHR N/A
- MDGL N/A
- Industry
- ACHR Aerospace
- MDGL Biotechnology: Pharmaceutical Preparations
- Sector
- ACHR Industrials
- MDGL Health Care
- Exchange
- ACHR Nasdaq
- MDGL Nasdaq
- Market Cap
- ACHR 6.4B
- MDGL 6.1B
- IPO Year
- ACHR N/A
- MDGL N/A
- Fundamental
- Price
- ACHR $10.61
- MDGL $314.31
- Analyst Decision
- ACHR Strong Buy
- MDGL Strong Buy
- Analyst Count
- ACHR 8
- MDGL 9
- Target Price
- ACHR $13.13
- MDGL $420.63
- AVG Volume (30 Days)
- ACHR 42.7M
- MDGL 286.7K
- Earning Date
- ACHR 08-07-2025
- MDGL 08-06-2025
- Dividend Yield
- ACHR N/A
- MDGL N/A
- EPS Growth
- ACHR N/A
- MDGL N/A
- EPS
- ACHR N/A
- MDGL N/A
- Revenue
- ACHR N/A
- MDGL $317,383,000.00
- Revenue This Year
- ACHR N/A
- MDGL $286.17
- Revenue Next Year
- ACHR N/A
- MDGL $64.17
- P/E Ratio
- ACHR N/A
- MDGL N/A
- Revenue Growth
- ACHR N/A
- MDGL N/A
- 52 Week Low
- ACHR $2.82
- MDGL $200.63
- 52 Week High
- ACHR $13.92
- MDGL $377.46
- Technical
- Relative Strength Index (RSI)
- ACHR 53.08
- MDGL 64.53
- Support Level
- ACHR $9.76
- MDGL $284.02
- Resistance Level
- ACHR $11.06
- MDGL $311.21
- Average True Range (ATR)
- ACHR 0.58
- MDGL 11.94
- MACD
- ACHR 0.02
- MDGL 2.74
- Stochastic Oscillator
- ACHR 63.81
- MDGL 100.00
About ACHR Archer Aviation Inc.
Archer Aviation Inc advances the benefits of sustainable air mobility. The company is engaged in designing and developing a fully electric vertical takeoff and landing eVTOL aircraft for use in UAM networks. It is creating an electric airline that moves people throughout cities in a quick, safe, sustainable, and cost-effective manner.
About MDGL Madrigal Pharmaceuticals Inc.
Madrigal Pharmaceuticals Inc is a biopharmaceutical company focused on delivering novel therapeutics for metabolic dysfunction-associated steatohepatitis (MASH), a serious liver disease with high unmet medical need that can lead to cirrhosis, liver failure, and premature mortality. The company's medication, Rezdiffra (resmetirom), is a once-daily, oral, liver-directed thyroid hormone receptor agonist designed to target key underlying causes of MASH.